Asked by: Siân Berry (Green Party - Brighton Pavilion)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with (a) the Joint Committee on Vaccination and Immunisation and (b) other experts on the potential merits of offering the Covid-19 booster vaccine to frontline healthcare workers over 65 years old.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
As with all United Kingdom vaccination programmes, the decision on which groups are eligible for a particular part of the programme is only made following careful consideration of the groups most at risk of illness, severe illness, or death, as a consequence of infection. The Joint Committee on Vaccination and Immunisation (JCVI) advised that COVID-19 vaccination should be offered to the following individuals in autumn 2024:
- adults aged 65 years old and over;
- residents in a care home for older adults; and
- persons aged six months to 64 years old in a clinical risk group, as defined in the COVID-19 chapter of the Green Book.
My Rt hon. Friend, the Secretary of State for Health and Social Care accepted the JCVI’s advice for COVID-19 vaccination in autumn 2024, and so COVID-19 vaccination will be offered to all adults aged 65 years old and over in the upcoming campaign.
Asked by: Neil Duncan-Jordan (Labour - Poole)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will include (a) unpaid family carers and (b) household contacts of immuno-suppressed individuals in the covid-19 vaccination programme.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The primary aim of the autumn 2024 COVID-19 vaccination programme remains the prevention of severe illness, hospitalisations, and deaths, arising from COVID-19. On 2 August 2024 the Government accepted the advice of the independent Joint Committee on Vaccination and Immunisation (JCVI) to offer a COVID-19 vaccination to those aged 65 years old or over, those living in care homes for older adults, and those aged between six months and 64 years old who are in a clinical risk group in England this autumn. Additionally, vaccination will be offered to all frontline health and social care workers, as well as staff in care homes for older adults.
There are no plans to offer a COVID-19 vaccination to unpaid carers, including young carers, or the families and household contacts of people with immunosuppression, during the autumn 2024 campaign in England. Unpaid carers and household contacts of those with immunosuppression have previously been offered vaccination on the basis that it indirectly protected those more vulnerable with whom they are in contact. The JCVI advice for autumn 2024 is that in the era of highly transmissible Omicron sub-variants, any protection offered by the vaccines against transmission of infection from one person to another is expected to be extremely limited. The indirect benefits of vaccination in these groups, vaccinating an individual to reduce the risk of severe disease in other people, are therefore less evident than in previous years.
Asked by: Daisy Cooper (Liberal Democrat - St Albans)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make it his policy to extend the covid-19 booster vaccination this autumn to (a) unpaid and (b) young carers.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The primary aim of the autumn 2024 COVID-19 vaccination programme remains the prevention of severe illness, hospitalisations, and deaths, arising from COVID-19. On 2 August 2024 the Government accepted the advice of the independent Joint Committee on Vaccination and Immunisation (JCVI) to offer a COVID-19 vaccination to those aged 65 years old or over, those living in care homes for older adults, and those aged between six months and 64 years old who are in a clinical risk group in England this autumn. Additionally, vaccination will be offered to all frontline health and social care workers, as well as staff in care homes for older adults.
There are no plans to offer a COVID-19 vaccination to unpaid carers, including young carers, or the families and household contacts of people with immunosuppression, during the autumn 2024 campaign in England. Unpaid carers and household contacts of those with immunosuppression have previously been offered vaccination on the basis that it indirectly protected those more vulnerable with whom they are in contact. The JCVI advice for autumn 2024 is that in the era of highly transmissible Omicron sub-variants, any protection offered by the vaccines against transmission of infection from one person to another is expected to be extremely limited. The indirect benefits of vaccination in these groups, vaccinating an individual to reduce the risk of severe disease in other people, are therefore less evident than in previous years.
Asked by: Rachel Gilmour (Liberal Democrat - Tiverton and Minehead)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to provide covid-19 vaccinations to the (a) families and (b) carers of patients with immunosuppressant diseases.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The primary aim of the autumn 2024 COVID-19 vaccination programme remains the prevention of severe illness, hospitalisations, and deaths, arising from COVID-19. On 2 August 2024 the Government accepted the advice of the independent Joint Committee on Vaccination and Immunisation (JCVI) to offer a COVID-19 vaccination to those aged 65 years old or over, those living in care homes for older adults, and those aged between six months and 64 years old who are in a clinical risk group in England this autumn. Additionally, vaccination will be offered to all frontline health and social care workers, as well as staff in care homes for older adults.
There are no plans to offer a COVID-19 vaccination to unpaid carers, including young carers, or the families and household contacts of people with immunosuppression, during the autumn 2024 campaign in England. Unpaid carers and household contacts of those with immunosuppression have previously been offered vaccination on the basis that it indirectly protected those more vulnerable with whom they are in contact. The JCVI advice for autumn 2024 is that in the era of highly transmissible Omicron sub-variants, any protection offered by the vaccines against transmission of infection from one person to another is expected to be extremely limited. The indirect benefits of vaccination in these groups, vaccinating an individual to reduce the risk of severe disease in other people, are therefore less evident than in previous years.
Asked by: Charlotte Nichols (Labour - Warrington North)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will allow contacts of people with immunosuppression to be eligible for the covid-19 vaccination programme in autumn 2024.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
The primary aim of the autumn 2024 COVID-19 vaccination programme remains the prevention of severe illness, hospitalisations, and deaths, arising from COVID-19. On 2 August 2024 the Government accepted the advice of the independent Joint Committee on Vaccination and Immunisation (JCVI) to offer a COVID-19 vaccination to those aged 65 years old or over, those living in care homes for older adults, and those aged between six months and 64 years old who are in a clinical risk group in England this autumn. Additionally, vaccination will be offered to all frontline health and social care workers, as well as staff in care homes for older adults.
There are no plans to offer a COVID-19 vaccination to unpaid carers, including young carers, or the families and household contacts of people with immunosuppression, during the autumn 2024 campaign in England. Unpaid carers and household contacts of those with immunosuppression have previously been offered vaccination on the basis that it indirectly protected those more vulnerable with whom they are in contact. The JCVI advice for autumn 2024 is that in the era of highly transmissible Omicron sub-variants, any protection offered by the vaccines against transmission of infection from one person to another is expected to be extremely limited. The indirect benefits of vaccination in these groups, vaccinating an individual to reduce the risk of severe disease in other people, are therefore less evident than in previous years.
Asked by: Kim Leadbeater (Labour - Spen Valley)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the evidential basis is for not including household members of people who are clinically vulnerable within the eligibility criteria for covid-19 booster vaccinations.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
As with all United Kingdom vaccination programmes, the decision of which groups are eligible for a particular part of the programme is made following careful consideration of the groups most at risk of illness, severe illness, or death, as a consequence of infection.
As currently available COVID-19 vaccines provide limited protection against transmission and mild or asymptomatic disease, the focus of the programme is on offering vaccination to those most likely to directly benefit, particularly those with underlying health conditions that increase their risk of hospitalisation following infection.
The benefit of vaccinating an individual to reduce the risk of severe disease in other people is much less evident now compared with previous years. For this reason, the Joint Committee on Vaccination and Immunisation did not advise an offer of COVID-19 vaccinations in autumn 2024 for household contacts of people with immunosuppression.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential risk of people with partial trisomy experiencing heart complications following an mRNA vaccine; and if his Department will take steps to ensure that the decision of Mr Justice Hayden in the Court of Protection is communicated to all health service professionals.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
There has been no formal review of the potential risk of people with partial trisomy experiencing heart complications following an mRNA vaccine, although the safety of vaccines is continually monitored by the independent Medicine and Healthcare products Regulatory Agency (MHRA). The MHRA conducted detailed analysis of all Yellow Card reports of heart inflammation, specifically myocarditis and pericarditis, which occurred following an mRNA vaccine. Details of these analyses were published weekly in the MHRA’s Coronavirus Vaccine - Summary of Yellow Card Reporting, which is available at the following link:
These analyses did not identify a specific safety concern in relation to patients with congenital conditions, such as trisomy, who received an mRNA vaccine.
In relation to the judgement of the Hon. Mr Justice Hayden, there are currently no plans to communicate the decision from this specific case to all healthcare professionals. As with all vaccines, should any information indicate a possible new safety concern, the system is well placed to rapidly and thoroughly investigate this, with advice for healthcare professionals and patients updated where appropriate.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, on what date NHS England informed patients receiving the Oxford-AstraZeneca Covid-19 vaccine that there were safety risks of vaccine-induced thrombosis with thrombocytopenia associated with the vaccine.
Answered by Maria Caulfield
To ensure informed consent was given by patients who received the AstraZeneca COVID-19 vaccine, all vaccination sites were instructed to follow consent guidance in line with the recommendations set out in chapter two of the UK Health Security Agency Green Book on vaccinations and immunisations.
Healthcare organisations administering any COVID-19 vaccinations are responsible for drawing up their own policies for obtaining informed consent, and health professionals overseeing or administering COVID-19 vaccines are responsible for ensuring that valid consent has been obtained. This would normally involve a discussion with the clinician prior to the administration of the vaccine, and individuals will also have had access to guides and patient information leaflets which provided details about the vaccine, how it is administered, possible side effects, and other warnings and precautions to take.
Regarding the very rare adverse events of concurrent thrombosis and thrombocytopenia associated with the AstraZeneca COVID-19 vaccine, NHS England notified healthcare organisations administering the COVID-19 vaccinations immediately following the updated advice from the independent Joint Committee on Vaccination and Immunisation published on 7 April 2021, and then again following updated advice on 7 May 2021. In these updates, sent via system letters, NHS England set out the next steps for healthcare organisations and clinicians, including on the consent process.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps NHS England took to ensure that informed consent was given by recipients of the Oxford-AstraZeneca covid-19 vaccine.
Answered by Maria Caulfield
To ensure informed consent was given by patients who received the AstraZeneca COVID-19 vaccine, all vaccination sites were instructed to follow consent guidance in line with the recommendations set out in chapter two of the UK Health Security Agency Green Book on vaccinations and immunisations.
Healthcare organisations administering any COVID-19 vaccinations are responsible for drawing up their own policies for obtaining informed consent, and health professionals overseeing or administering COVID-19 vaccines are responsible for ensuring that valid consent has been obtained. This would normally involve a discussion with the clinician prior to the administration of the vaccine, and individuals will also have had access to guides and patient information leaflets which provided details about the vaccine, how it is administered, possible side effects, and other warnings and precautions to take.
Regarding the very rare adverse events of concurrent thrombosis and thrombocytopenia associated with the AstraZeneca COVID-19 vaccine, NHS England notified healthcare organisations administering the COVID-19 vaccinations immediately following the updated advice from the independent Joint Committee on Vaccination and Immunisation published on 7 April 2021, and then again following updated advice on 7 May 2021. In these updates, sent via system letters, NHS England set out the next steps for healthcare organisations and clinicians, including on the consent process.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether (a) his Department and (b) the Medicines and Healthcare products Regulatory Agency has received data from Astra Zeneca on the potential serious adverse effects of its covid-19 vaccine for a small number of recipients.
Answered by Maria Caulfield
The Department has not directly received data from AstraZeneca regarding potential adverse effects of their COVID-19 vaccine Vaxzevria, as it is not the appropriate body to receive this information. It instead relies on the expert advice of the Medicines and Healthcare products Regulatory Agency (MHRA).
All vaccine manufacturers have a legal responsibility to mitigate risk and monitor the safety and performance of vaccines throughout the product lifecycle. This includes a legal responsibility to transmit reports of suspected adverse reactions received directly to the MHRA. Following the MHRA’s receipt of the first Yellow Card reports of suspected thrombosis and associated thrombocytopaenia associated with the Vaxzevria vaccine in February 2021, AstraZeneca provided the Commission on Human Medicines’ Vaccine Benefit Risk Expert Working Group an analysis of the age stratified risk of thrombosis with thrombocytopenia associated with the AstraZeneca vaccine. This was assessed by the Commission on Human Medicines, with the Patient Information updated to state the risks of these events.